德源药业
(832735)
| 流通市值：19.45亿 | | | 总市值：22.00亿 |
| 流通股本：6917.15万 | | | 总股本：7824.50万 |
| 报告期 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 432,481,805.86 | 209,789,353.15 | 709,207,754.74 | 527,964,172.48 |
| 营业收入 | 432,481,805.86 | 209,789,353.15 | 709,207,754.74 | 527,964,172.48 |
| 二、营业总成本 | 343,009,605.23 | 167,530,364.26 | 579,163,604.31 | 439,530,508.25 |
| 营业成本 | 66,662,407.56 | 35,215,272.02 | 128,578,495.3 | 95,422,546.26 |
| 税金及附加 | 6,171,507.94 | 3,579,361.14 | 9,780,887.89 | 7,488,095.58 |
| 销售费用 | 184,891,496.05 | 88,987,947.07 | 286,950,720.25 | 220,451,994.49 |
| 管理费用 | 23,268,416.72 | 12,415,370.49 | 47,177,709.44 | 36,087,905.27 |
| 研发费用 | 64,855,171.5 | 28,327,072.1 | 109,566,694.77 | 82,001,063.31 |
| 财务费用 | -2,839,394.54 | -994,658.56 | -2,890,903.34 | -1,921,096.66 |
| 其中:利息费用 | 376,823.56 | 197,609.03 | 777,113.22 | 565,572.07 |
| 其中:利息收入 | 3,245,691.73 | 1,203,987.39 | 3,724,864.24 | 2,525,998.69 |
| 加:公允价值变动收益 | 317,013.32 | - | 75,236.59 | 1,014,097.83 |
| 加:投资收益 | 630,228.06 | 325,711.38 | 5,897,182.46 | 3,543,149.63 |
| 资产处置收益 | - | - | 3,477.57 | -8,450.43 |
| 信用减值损失(新) | -1,714,987.28 | -989,558.8 | -2,122,148.05 | -1,671,330.05 |
| 其他收益 | 6,132,258.17 | 743,132.73 | 10,519,382.28 | 8,436,421.61 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 94,836,712.9 | 42,338,274.2 | 144,417,281.28 | 99,747,552.82 |
| 加:营业外收入 | 126,400.2 | 47,747.79 | 286,626.09 | 51,108.69 |
| 减:营业外支出 | 75,699.72 | 20,064.64 | 327,159.99 | 90,354.77 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 94,887,413.38 | 42,365,957.35 | 144,376,747.38 | 99,708,306.74 |
| 减:所得税费用 | 14,693,359.67 | 6,911,776.83 | 6,393,820.92 | 15,206,747.24 |
| 六、净利润 | 80,194,053.71 | 35,454,180.52 | 137,982,926.46 | 84,501,559.5 |
| 持续经营净利润 | 80,194,053.71 | 35,454,180.52 | 137,982,926.46 | 84,501,559.5 |
| 归属于母公司股东的净利润 | 80,194,053.71 | 35,454,180.52 | 137,982,926.46 | 84,501,559.5 |
| (一)基本每股收益 | 1.03 | 0.46 | 1.8 | 1.1 |
| (二)稀释每股收益 | 1.03 | 0.46 | 1.79 | 1.1 |
| 九、综合收益总额 | 80,194,053.71 | 35,454,180.52 | 137,982,926.46 | 84,501,559.5 |
| 归属于母公司股东的综合收益总额 | 80,194,053.71 | 35,454,180.52 | 137,982,926.46 | 84,501,559.5 |
| 公告日期 | 2024-08-28 | 2024-04-24 | 2024-03-29 | 2023-10-23 |
| 审计意见(境内) | | | 标准无保留意见 | |